We value your privacy

We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.

Research · 9 min read

Menopause care is going mainstream in state law: what's changing on coverage, education and work

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published · Updated

Statehouses are moving on menopause coverage, education and work: what Illinois has enacted, what is pending in Pennsylvania, and what to ask your insurer. A federal survey also shows how few symptomatic women ages 40 to 60 currently take a prescription, and we look at how ACOG's new guidance fits in.

Menopause care is no longer only a clinic-room conversation. State lawmakers have been introducing bills on insurance coverage, public education, and workplace accommodations, and some of that work is already in statute. The bills are not a diagnosis, and they are not a treatment plan. They are an attempt to make it less a matter of luck whether someone can get a visit, fill a prescription, or stay at work when symptoms are disruptive.

This is not legal advice, and it is not a prediction about what any legislature will pass. Bill and law status below is as of November 18, 2026, based on official legislative records checked that day. What a plan actually covers still depends on the final text of any law, on your own policy, and on a conversation with your insurer or benefits office.

Pennsylvania's package, and where the bills stand

In late September 2026, Pennsylvania representatives held a capitol rally around a package of menopause bills. The Guardian, in a November 17 feature by Anna North, described it as one of the more ambitious state efforts. A September 30 Pennsylvania Capital-Star report by Whitney Downard named the bills and their sponsors. Official General Assembly pages, checked November 18, 2026, confirm the numbers and status. None of the seven bills has become law.

Rep. Liz Hanbidge is the prime sponsor of three bills: House Bill 1411, which would direct the Department of Health to provide perimenopause and menopause education, passed the House on October 6, 189-14, and was referred to the Senate Health and Human Services Committee on October 13; House Bill 1346, which would require health insurance policies, as the bill defines them, to cover menopause treatment, subject to each policy's medical-necessity, cost-sharing and utilization-review terms, passed the House on October 7, 146-57, and was referred to the Senate Banking and Insurance Committee on October 26; and House Bill 1244, which would require insurance coverage for pelvic floor therapy, received first consideration in the House on September 29 and was laid on the table the same day. It has not passed the House.

Rep. Morgan Cephas is the prime sponsor of House Bill 1345, which would provide Medical Assistance coverage for menopause treatments, subject to federal approval, and House Bill 2135, which would require employers to accommodate pregnancy-related and menopause-related conditions. Both passed the House on October 7, 193-10 and 125-78 respectively. HB 1345 was referred to Senate Health and Human Services on October 26; HB 2135 was referred to Senate Labor and Industry the same day.

Rep. Melissa Shusterman, who according to The Guardian announced the package at the September rally, is the prime sponsor of House Bill 1827, on coverage of screening, prevention, and treatment for osteoporosis related to menopause, and House Bill 2545, which would require health insurance policies to cover FDA-approved vaginal estrogen products for menopausal symptoms and, in the bill's words, for "the prevention of urinary tract infections in individuals with menopause," subject to each policy's medical-necessity, cost-sharing and utilization-review terms. Both passed the House on October 21, 148-55 and 153-50 respectively, and were referred to Senate Banking and Insurance on October 27.

Six of the seven bills have passed the House and sit in Senate committees. One remains in the House. Referral to committee is not enactment. Pennsylvania's 2025-2026 legislative session ends November 30, 2026, and a bill that has not passed both chambers by then does not carry over; it would have to be reintroduced, likely under new bill numbers, in the new session that begins in January 2027. Whether any of these becomes law, and in what form, is not settled.

Illinois has already acted — on a split timeline

Illinois is further along, and the dates matter. House Bill 5284, the Illinois Menopause Equity and Care Act, was approved by the governor on August 7, 2026, and became Public Act 104-0793. The enrolled act says it takes effect January 1, 2027, except that changes to two sections of the Illinois Insurance Code take effect January 1, 2028.

The January 1, 2027, date covers workplace accommodations and related provisions. The act amends the Illinois Human Rights Act to define a "menopause-related condition" as perimenopause, menopause, and associated medical or symptomatic conditions, including vasomotor symptoms, sleep disruption, cognitive or mood changes, and osteoporosis-related changes. It extends the state's existing framework for reasonable workplace accommodations so that those rights include menopause-related conditions. Examples written into the act include flexible scheduling or modified work hours, and a temperature- or climate-adjusted workspace, among other adjustments, unless an employer can show an undue hardship. The act also directs the Illinois Department of Public Health to develop public educational materials on menopause and perimenopause.

The later date is about coverage, and it amends coverage rules Illinois already has. As the enrolled act prints the existing Insurance Code, group and individual accident and health policies and managed care plans amended, delivered, issued, or renewed on or after January 1, 2026 must already cover medically necessary hormonal and non-hormonal therapy to treat menopausal symptoms when a qualified, licensed health care provider recommends it and the statute's other conditions are met (215 ILCS 5/356z.56), and certain policies covering more than 25 employees must cover an annual menopause health visit for people 45 and older, generally without cost-sharing (215 ILCS 5/356z.74). Beginning January 1, 2028, the act changes those two sections: it extends them to perimenopause, extends the therapy section to menopausal and perimenopausal "conditions" as well as symptoms, adds that covered therapy must be prescribed in accordance with current evidence-based guidelines, and adds that coverage shall include medications for menopause-related osteoporosis and non-hormonal therapies for vasomotor symptoms.

Workplace accommodations in Illinois are set to take effect January 1, 2027; the Insurance Code changes take effect a year later, on top of the coverage rules already in place. If you work or have coverage in Illinois, the practical questions are still for your employer, your plan, and, if needed, a lawyer or advocacy organization. This article cannot tell you what your workplace owes you, or what your plan must pay.

The Guardian article also points to enacted or pending measures in other states. Jennifer Weiss-Wolf, author of a new book on menopause policy, told the Guardian that more than 60 state bills on menopause education, insurance coverage, or workplace accommodations have been introduced over the last two years; the article adds that at least 21 have passed. We were not able to independently count those bills for this draft, so those figures are attributed to that reporting. The Pennsylvania and Illinois records above are the ones we checked against official texts.

How many symptomatic women are currently taking a prescription?

A coverage or education bill would not matter much if most people with symptoms were already taking a prescription for them. A federal data brief suggests many are not.

NCHS Data Brief No. 575, published in October 2026 by Anjel Vahratian and Janine A. Clayton, analyzes 2025 National Health Interview Survey data. Among women ages 40 to 60 who were not currently pregnant, postpartum, or in surgical menopause, nearly one in two — 49.4% — reported menopausal symptoms in the past 12 months. Among those with symptoms, 15.6% said they were currently taking a prescription medication for them. Rounded, that is about 16%, or about one in six, or about 2.6 million women.

A few limits are built into that number. It counts people who said they were currently taking a prescription, not everyone who has ever tried treatment, used a nonprescription option, or finished a course of care. Interviewers could offer examples that included a nonhormonal drug, an SSRI marketed for hot flashes, estrogen hormone therapy, or birth control; this is not a hormone-therapy-only statistic. Symptoms and medication use were self-reported, and women in surgical menopause were excluded from the analysis.

The brief does not, by itself, explain why the share is that low. Reporting on the Pennsylvania bills describes overlapping barriers: symptoms that are still treated as awkward to discuss, uneven clinician training, and plans that may not cover a therapy a clinician recommends, or may cover one form and not another. Those are explanations people close to the bills have offered, not proof of any one person's reason for going without a prescription. If you have symptoms and have not been offered options, that is a reason to ask a clinician — and, separately, to ask what your plan covers.

What to ask your insurer

Insurance rules are specific to a plan. The questions below are general consumer questions. They are not a script for a Kindr visit, and they are not a claim about what any clinic, including Kindr, bills or accepts. A state coverage law, if and when it takes effect, would still be applied through your own policy, and state insurance mandates generally reach state-regulated insurance policies, not self-funded employer plans or federal programs such as Medicare. Ask your plan which kind you have.

You can ask whether the plan covers evaluation and treatment of menopause or perimenopause symptoms; which FDA-approved hormone therapies are covered, and whether that differs by pill, patch, gel, or other route; whether nonhormonal prescription options are covered; whether prior authorization, preferred products, quantity limits, or step-therapy rules apply; and what the exception or appeal process is if a covered product is delayed, not tolerated, or not available. If you have Medicaid, an employer plan, or a marketplace plan, ask whether the answer changes. Write down the date, the representative's name, and any case number, and have the name of any recommended therapy when you call.

How ACOG's October guidance fits

None of this replaces a clinical recommendation. In October 2026, the American College of Obstetricians and Gynecologists announced Clinical Practice Guideline 13, "Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms." ACOG's October 15 press release called it the most comprehensive menopause guidance the organization has issued to date. A November 17 Here & Now write-up on WBUR, which brought the guidance back into the news, said ACOG's new guidelines recommend "hormone therapy as a first-line treatment for many women experiencing menopause symptoms, including hot flashes and related sleep disturbances." That "first-line" wording is WBUR's, not ACOG's: ACOG's October 15 press release does not use it, and the guideline addresses vasomotor, sleep and mood symptoms rather than every menopause symptom. Guideline coauthor Robert P. Kauffman, MD, MSCP, FACOG, said hormone therapy "can be a great option—and in many cases, the best option—but may not be appropriate or helpful for every person experiencing menopausal symptoms."

We walked through that document in an earlier post. The guidance emphasizes shared decision-making: symptoms, age, medical history, baseline risks of cardiovascular disease, breast cancer, and blood clots, and the person's own goals. If hormone therapy is selected, ACOG recommends starting it before age 60 or within 10 years of the start of spontaneous menopause, in people without contraindications. Decisions about when and how to stop should also be individualized. The guidance reviews nonhormonal options for people who cannot or prefer not to use hormone therapy.

Hormone therapy isn't right for everyone: depending on age, timing, health history and the type used, it can raise the risk of blood clots, stroke and breast cancer, and estrogen without a progestogen raises the risk of uterine cancer in people who have a uterus.

A coverage law does not change those clinical limits. It may change whether a recommended option is easier to afford. Who should not take hormone therapy, and how timing and age factor in, are still questions for a clinician. We have written in more detail about who shouldn't take hormone therapy and timing and age.

Where Kindr fits

At Kindr Health, menopause and midlife care is clinician-led. If you are trying to sort out symptoms or whether hormone therapy or a nonhormonal option belongs in the conversation, a licensed clinician can take a history and talk through what may or may not be appropriate. Kindr Care patient intake is open now.

This article is not legal advice. Check bill or coverage questions with official sources, your insurer, or a qualified advisor.

This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping, or changing any medication. See our medical disclaimer.

Sources

Medically reviewed by Kindr Health Clinical Team
Last updated: November 18, 2026

Continue across the Kindr entity graph

Related evidence, peptides, and clinical tools on the same topic.

This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Keep reading

Research

Hormone therapy dispensing has more than doubled: what the new JAMA data mean for you

A new JAMA analysis of pharmacy dispensing, as reported by Science News, finds monthly hormone therapy dispensing to women aged 40 to 74 more than doubled since 2023, with growth in transdermal and vaginal estrogen while pills stayed flat, and we look at what that means for planning care

Research

Menopause equity: why so many women still fall through the cracks, and how to get the care you deserve

An AMWA position paper names gaps that still keep people from menopause care: training, screening, coverage, research and stigma. We look at what's changing in state law, a new academic post in British Columbia, and ACOG's guidance, and we offer a practical checklist for getting evaluated.

Research

Is it perimenopause? The 16 symptoms worth tracking (beyond hot flashes)

A newly validated 16-item scale groups perimenopause symptoms into four domains and asks what you have noticed over the past 30 days, well beyond hot flashes. Here's what it covers, what older checklists can miss, and how a month-long log may help a clinician visit.

Explore your next step

Kindr Care is being updated, and the exact clinical process will depend on the current care pathway.

Explore care options →